A multicenter, randomized, placebo-controlled, double-blind, parallel-group study, to assess efficacy, safety and immunogenicity of JNJ-64042056, a phosphorylated tau targeted active immunotherapy, in participants with preclinical Alzheimer's disease
Latest Information Update: 04 Sep 2026
At a glance
- Drugs ACI 35.030 (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms ReTain
- Sponsors AC Immune; Janssen-Cilag
Most Recent Events
- 07 Jul 2026 This trial has been suspended in Spain and France.
- 05 Jun 2026 Planned End Date changed from 22 Dec 2026 to 5 Jan 2027.
- 13 May 2026 Planned End Date changed from 7 Jul 2034 to 22 Dec 2026.